DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Clofarabine. Bioenvision/ILEX.

Author(s): Sternberg A

Affiliation(s): Academic Department of Haematology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, OX3 9DS, UK. stern@molbiol.ox.ac.uk

Publication date & source: 2003-12, Curr Opin Investig Drugs., 4(12):1479-87.

Publication type: Review

Clofarabine is a purine nucleoside antimetabolite under development by Bioenvision (under license from the Southern Research Institute) and ILEX for the potential treatment of solid tumors, acute myelogenous leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia. In September 2003, Bioenvision initiated a phase II trial in Europe in pediatric acute lymphoblastic leukemia, and in October 2003, ILEX submitted the first part of a rolling NDA to the FDA for the treatment of acute leukemia in children.

Page last updated: 2007-05-02

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017